HK Stock MarketDetailed Quotes

02607 SH PHARMA

Watchlist
  • 11.300
  • -0.020-0.18%
Not Open Apr 2 16:08 CST
41.90BMarket Cap8.52P/E (TTM)

About SH PHARMA Company

The company is a large pharmaceutical industry group listed in Shanghai and Hong Kong. The company advocates the core corporate values of “innovation, honesty, cooperation, tolerance and responsibility”, and is committed to persevere, improve people's healthy quality of life, and strive to become a leading brand drug manufacturer and health service provider that is respected and has a reputation in the industry. The company's main business is the pharmaceutical industry and pharmaceutical business. The company's main products: hydroxychloroquine sulfate tablets, injectable urastatin, gastric rejuvenation capsules, polysaccharide iron complex capsules, bifidobacteria trifecta active bacterial preparations. Corporate honors: “2023 Asia Pacific Quality Organization - Innovation Award”, the company won 27 national quality awards, 112 provincial and municipal quality awards, the “Fortune 500” list, and won the “Top 50 Global Pharmaceutical Companies”, “Top 25 Global Pharmaceutical Brands”, “China's Top 100 Pharmaceutical Industry Companies”, and “China's Top 100 Pharmaceutical Industry Companies”, and “Best Industrial Enterprise in China's Pharmaceutical R&D Product Line”, ranked 473rd among the 2020 Fortune Global 500, and is one of only two Chinese pharmaceutical companies; In “Fortune It ranked 57th in the 2020 Fortune China 500 published by “Fortune” (Chinese version); ranked 1009th in the 2020 Global Top 2000 Companies published by “Forbes”, and ranked 2nd in the overall strength of China Pharmaceutical Group.

Company Profile

Symbol02607
Company NameSH PHARMA
ISINCNE1000012B3
Listing DateMay 20, 2011
Issue Price23.00
Shares Offered664.21M share(s)
FoundedJan 18, 1994
Registered AddressChina
Chairmanqiuhua yang
Secretarytaohuangpeiqiao zhong
Audit InstitutionDeloitte Huayong Certified Public Accountants (Special General Partnership)
Company CategoryMainland registration of Mainland State-owned Assets control
Registered OfficeNo. 92, Zhangjiang Road, China (Shanghai) Pilot Free Trade Zone
Head Office and Principal Place of BusinessRoom 1918, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees49402
MarketHong Kong motherboard
Phone8621-63730908
Fax8621-63289333
Emailpharm@sphchina.com
Websitehttp://www.sphchina.com
BusinessPharmaceutical products of various dosage forms (including but not limited to tablets, capsules, aerosols, immunological preparations, granules, ointments, pills, oral solutions, inhalants, injections, liniments, tinctures, suppositories) (including but not limited to the development of chemical raw materials, chemical preparations, Chinese herbal medicines, proprietary Chinese medicines, Chinese herbal medicines, herbal medicines, biological products, narcotic drugs, psychotropic drugs, toxic drugs for medical use [appropriate to the scope of business], vaccines), health products, medical devices and related products Manufacturing and sales, pharmaceutical equipment manufacturing, sales and engineering installation, maintenance, warehousing and logistics, offshore , land and air freight forwarding business, industrial investment, asset management, provision of international economic and trade information and consulting services, leasing of own housing, and import and export business of various kinds of pharmaceuticals and related commodities and technology (the above involves licensed operations).

Company Executives

  • Name
  • Position
  • Salary
  • qiuhua yang
  • Chairman, Executive Director, Chairman of the Strategy Committee, Remuneration Committee Member
  • --
  • bo shen
  • President, Executive Director, Chief Financial Officer, Nomination Committee Members, Authorized Representative
  • --
  • yongzhong li
  • Executive President, Executive Director
  • --
  • ming dong
  • Executive Director
  • --
  • wenxue zhang
  • Non-executive Directors, Strategy Committee Members
  • --
  • chaoyang gu
  • Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members, Remuneration Committee Members
  • --
  • wenxun huo
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members
  • --
  • zhong wang
  • Independent Non-Executive Director, Remuneration Committee Chairman, Strategy Committee Member, Audit Committee Member
  • --
  • jun wan
  • Independent Non-Executive Director, Nomination Committee Members
  • --
  • youli xu
  • Chief Supervisor
  • --
  • weidong yu
  • Employee Representative Supervisor
  • --
  • jia ma
  • Auditors
  • --
  • yong zhao
  • VP
  • --
  • jianyi mao
  • VP
  • --
  • yaohua zhang
  • VP
  • --
  • tao zhong
  • VP, Joint Company Secretary, Board Secretary, Authorized Representative
  • --
  • dongming li
  • VP
  • --
  • maitiaili mai
  • VP
  • --
  • shuai shao
  • VP
  • --
  • peiqiao huang
  • Joint Company Secretary, Legal Process Agent
  • --

Market Insights

Robotics Investment Opportunities Robotics Investment Opportunities

Robotics includes companies involved in the design, creation, and manufacture of robots. These machines can perform tasks autonomously or semi-autonomously, often with the aim of improving efficiency, productivity, and safety across various industries. Robotics companies are rapidly innovating new technology with applications across many industries. They offer opportunities for growth and efficiency, align with long-term automation trends, and have the potential for disruption in emerging markets, making them appealing to investors. Robotics includes companies involved in the design, creation, and manufacture of robots. These machines can perform tasks autonomously or semi-autonomously, often with the aim of improving efficiency, productivity, and safety across various industries. Robotics companies are rapidly innovating new technology with applications across many industries. They offer opportunities for growth and efficiency, align with long-term automation trends, and have the potential for disruption in emerging markets, making them appealing to investors.

No. Symbol % Year-to-date
DOBOT
02432
+197.26%
SY HOLDINGS
06069
+96.64%
MEDBOT-B
02252
+83.60%
4
XPENG-W
09868
+77.71%
5
HORIZONROBOT-W
09660
+68.89%
Log In for the Full List
Unlock Now

Investment Course

Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th

Discussing

北水爆買！中國資產能否延續漲勢？
3月17日早盤，地產代理、物業服務及管理等板塊漲幅明顯，貝殼-W早盤漲逾4%，碧桂園服務漲逾9%。政策消息面上，兩部門發文落實專項債支持收地，中房協組織民營房企座談會。中國資產本輪火爆行情還能持續多久？你會如何投資？ Show More
Review on February 27...

Positive signs keep on coming! China's assets explode across the board

Following the announcement of a series of previous stimulus policies, and DeepSeek's popularity with its low cost and high performance advantages, China Securities sounded the horn of counterattack this year.